BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Patients Now Enrolling in Phase I Human Trial for Quintessence Biosciences, Inc. Cancer Drug, QBI-139


3/26/2009 10:46:57 AM

MADISON, WISCONSIN— Quintessence Biosciences, Inc. announced today that the Phase I trial of its Investigational New Drug (IND), QBI-139, has begun enrolling patients. The Phase I Trial is taking place at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC) in Madison. QBI-139 is the first of the Company’s EVade™ Ribonuclease drug candidates to reach the clinic.

Unlike conventional chemotherapies, the EVade™ Ribonuclease technology provides an opportunity to attack RNA in cancer cells, an exciting new drug target. QBI-139 is nearly identical to a human protein, pancreatic ribonuclease 1. In preclinical disease models, QBI-139 has shown significant tumor growth inhibition against human pancreatic, non-small cell lung, prostate, and ovarian solid tumors.

Quintessence Biosciences will not directly enroll patients. Potential enrollees should contact UWCCC Cancer Connect by email (uwccc@uwccc.wisc.edu) or by phone (800-622-8922 or 608-262-5223) to request information (Unique Protocol ID # CO 08912).

The attached document outlines basic information for potential enrollees. The information is also available on the Quintessence Biosciences, Inc. web site at www.quintbio.com.

“The start of the Phase I QBI-139 trial represents the culmination of years of research and an opportunity to demonstrate the promise of a new class of cancer therapies,” said Quintessence Biosciences President Dr. Laura Strong. “We are optimistic that QBI-139 will provide a new means to help patients with cancer. There is a clear need for drugs that attack cancer in new ways, and ribonuclease therapies are positioned to accomplish that goal.”

About Quintessence Biosciences, Inc.

Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of proprietary cancer therapies based on the EVade™ Ribonuclease technology. In December 2008, Quintessence Biosciences received approval from the US Food and Drug Administration to enter a Phase 1 clinical trial on the Company’s first drug candidate, QBI-139. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES